Before you start trading Transenterix shares, we suggest you learn more about this company and its economic environment, in order to help you succeed in your analysis of its share price. In a detailed article on this stock, we will introduce you to the company and its business sector with its main sources of profit. We will also present the major competitors of this company in the world as well as some events that have recently influenced its share price. Of course, we will also guide you in the realization of your fundamental analysis of this stock with the data that you must follow in priority to succeed.
First of all, we will of course follow closely the development of new products by the Transenterix group with the marketing of new devices and the obtaining of the necessary authorizations by the world's medical and health authorities.
The development of the group's activities around the world is also an element to be followed and we will focus here on the efforts and operations implemented to obtain new contracts and markets abroad.
Like all companies specializing in the medical and paramedical field, regulations in this sector are at the heart of the Transenterix Group's issues and you must therefore take into account any changes in these regulations over time.
Of course, we will also keep an eye on what is happening with this group's competitors with all the data concerning the production of devices equivalent to those of Transenterix and likely to make it lose market share.
Of course, it will be possible to obtain information on Transenterix's growth strategies and long-term objectives by visiting its official website in the section reserved for investors.
Finally, the group's financial results and interim or annual balance sheets should also be systematically consulted in order to verify its growth and the maintenance of its operational profitability.
We will now take a closer look at Transenterix and its activities. Indeed, it is above all by having a good knowledge of the sector in which this company operates and its main sources of profit that you will be able to anticipate its future stock market fluctuations.
The Transenterix Group is an American company specializing in the medical device sector.
More specifically, Transenterix focuses on the development and commercialization of the ALF-X surgical robotic system and the SurgiBot system.
The ALF-X system produced and developed by this company is a multi-port robotic surgery system that allows several robotic arms to control surgical instruments and a camera. This system is equipped with state-of-the-art technology that allows surgeons to perform haptic feedback and move the camera according to eye movement. This system also reproduces laparoscopic movement and integrates high-definition three-dimensional vision technology. Finally, this system offers responsible savings to hospitals through robotic technology with reusable instruments.
The SurgiBot system is also a system designed for robot-assisted surgery but with a single incision on the patient's side.
It should also be noted that this company develops and produces laparoscopic surgical instruments that are used in abdominal surgery such as scissors, forceps, staplers and various instruments for suction and irrigation.
To date, the Transenterix group employs 163 people.
In addition to knowing Transenterix well, you should also have a good knowledge of its main competitors on the market. In the medical robotics sector, the following companies can be mentioned
This American company specializes in the design and production of medical robots and is listed on the Nasdaq 100 stock market index. It is this company that produces and markets the Da Vinci robot, which is sold at more than one million dollars per unit. In 2003, the company merged with its competitor Computer Motion.
This privately held American company specializes in surgical products with a focus on robotics. It offers access to minimally invasive surgery for patients and manufactures and markets the Flex Robotic System, a robot-assisted platform that provides surgeons with single-site access and visualization of hard-to-reach anatomical locations.
This is another US company engaged in the design and manufacture of medical robotics for positioning and control of catheter-based technologies. It was founded in 2002 in the area of developing catheter manipulation tools by combining robotic technology and computerized motion.
This Canadian company specializes in the development of surgical systems for minimally invasive surgery without large incisions. The company is developing the SPORT surgical system, which is a single-port, single-incision robotic system that allows for teleoperation or remote surgery. This system integrates a robotic platform controlled by the surgeon and which includes a high-definition three-dimensional vision system and multi-articulated instruments as well as a workstation that provides the surgeon with an ergonomic interface and a 3D endoscopic view of the patient's body.
Finally, this American company, formerly known as StelCells Inc, specializes in medical devices. Its activities include the research, design, development and commercialization of transformational micro-robotic medical technologies that utilize the artificial and natural light of the human body. The company is currently developing two major product candidates with the Self-Cleaning Shunt or SCS for the treatment of hydrocephalus and normal pressure hydrocephalus and TipCat which is a self-propelled semi-disposable endoscope that is under development for colonoscopy procedures.
To help you understand how Transenterix is likely to accelerate its growth and face future threats and challenges, we now propose to discover its major advantages and disadvantages.
As far as the advantages and therefore the strengths of this company are concerned, the following elements are particularly noteworthy:
Of course, the Transenterix group also has weaknesses that you should be aware of before taking a position on this stock. Here is a summary:
The analysis of the evolution of the net earnings per share of Transenterix Group is interesting to know the interest that this value can have for the investors. Thus and in 2019, this net profit per share was -4.22 dollars or -35% per share.
If, by buying Transenterix shares, you are primarily betting on an increase in the value of this stock, you can also implement a short strategy on this stock using CFDs. These contracts for difference can give you the opportunity to take positions on both the rise and fall of this price and thus profit from all market movements.
eToro is a multi-asset platform which offers both investing in stocks and cryptoassets, as well as trading CFDs.
Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail CFD accounts lose money. You should consider whether you can afford to take the high risk of losing your money.
Past performance is not an indication of future results. Trading history presented is less than 5 complete years and may not suffice as basis for investment decision.
Copy trading is a portfolio management service, provided by eToro (Europe) Ltd., which is authorised and regulated by the Cyprus Securities and Exchange Commission.
Cryptoasset investing is unregulated in some EU countries and the UK. No consumer protection. Your capital is at risk.
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro.
